Bottom line
PBE vs IBBQ: the short answer
PBE (Invesco Biotechnology & Genome ETF) and IBBQ (Invesco Nasdaq Biotechnology ETF) share a meaningful slice of their top holdings — about 56% by weight.
But IBBQ is far broader, holding 261 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
IBBQ is cheaper at 0.19% vs 0.59% — a difference of $40 a year per $10,000 invested.
Over one year, PBE returned +24.7% vs −0.6% for IBBQ (reporting dates differ).
Updated Nov 19, 2026
PBE vs IBBQ side by side
| PBE | IBBQ | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.59% | 0.19% |
| Annual cost per $10k | $59 | $19 |
| 10-yr cost on $10k (prospectus) | $738 | $242 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | +24.7% | −0.6% |
| 5-yr return (annualized) | +3.4% | — |
| 10-yr return (annualized) | +5.2% | — |
| Best quarter | +25.3% | +12.0% |
| Worst quarter | −24.3% | −11.7% |
| Net assets (fund) | $281.9M | $67.4M |
| Number of holdings | 33 | 261 |
| Portfolio turnover | 103% | 17% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PBE | IBBQ | Difference |
|---|---|---|---|
| 2024 | +1.1% | −0.6% | +1.7% |
| 2023 | +3.7% | +4.5% | −0.8% |
| 2022 | −10.8% | −10.2% | −0.5% |
Source: Fund prospectus bar charts
Holdings overlap
14 of PBE's top 25 holdings also appear in IBBQ's top 25.
| Holding | PBE | IBBQ |
|---|---|---|
| Invesco Private Prime Fund | 12.89% | 14.20% |
| Regeneron Pharmaceuticals, Inc. | 5.47% | 5.08% |
| Amgen Inc. | 5.22% | 7.10% |
| Vertex Pharmaceuticals Inc. | 4.99% | 7.38% |
| Invesco Private Government Fund | 4.97% | 5.48% |
| Royalty Pharma PLC | 4.94% | 1.90% |
| Biogen Inc. | 4.79% | 2.29% |
| Gilead Sciences, Inc. | 4.43% | 7.39% |
| United Therapeutics Corp. | 4.08% | 1.94% |
| Illumina, Inc. | 3.51% | 1.98% |
| Alnylam Pharmaceuticals, Inc. | 3.17% | 3.19% |
| Incyte Corp. | 3.06% | 1.53% |
| Neurocrine Biosciences, Inc. | 2.66% | 1.26% |
| Exelixis, Inc. | 2.64% | 1.04% |
Source: SEC Form N-PORT
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
IBBQ top 10
- Invesco Private Prime Fund — 14.20%
- Gilead Sciences, Inc. — 7.39%
- Vertex Pharmaceuticals Inc. — 7.38%
- Amgen Inc. — 7.10%
- Invesco Private Government Fund — 5.48%
- Regeneron Pharmaceuticals, Inc. — 5.08%
- Alnylam Pharmaceuticals, Inc. — 3.19%
- Revolution Medicines, Inc. — 2.48%
- Biogen Inc. — 2.29%
- Illumina, Inc. — 1.98%
FAQ
What is the difference between PBE and IBBQ?
Which is cheaper, PBE or IBBQ?
Should I own both PBE and IBBQ?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.